Drugs / Abequolixron
Abequolixron
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05911308 | Apr → Oct 2024 | non-small cell lung carcinoma | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02922764 | Nov 2016 → Jan 2025 | endometrial cancer, non-small cell lung carcinoma | Inspirna, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abequolixron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911308 ↗ |
| Known as | RGX-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02922764 ↗ |
| Known as | SB-742881 | ChEMBL registry synonym — accepted as the source's own label CHEMBL573677 ↗ |
| Action | Activate | “RGX-104 activates LXR” NCT02922764 ↗ |
| Modality | Small molecule | “RGX-104, an oral small molecule targeting the liver X receptor (LXR)” NCT02922764 ↗ |
| Route | Oral | “oral small molecule targeting the liver X receptor (LXR)” NCT02922764 ↗ |